2014

Clarus Ventures Closes $660 Million Fund Brings assets under management to $1.2 billion



    CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ --
 Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture
 capital firm, announced today the single close of Clarus Lifesciences II,
 L.P. ("Clarus II"), a $660 million fund in Limited Partner commitments.
 This is the second investment fund formed and managed by Clarus Ventures,
 since the firm was established in 2005.
 
     Clarus II will invest $20-60 million in biotechnology, specialty
 pharmaceutical and medical technology companies that are developing
 innovative products for the treatment of human diseases. The firm's first
 fund has committed 90 percent of its proceeds to date.
 
     "We have effectively completed the deployment of our first fund and
 built a diversified portfolio of exciting companies," said Robert Liptak, a
 Clarus Ventures Managing Director. "These include companies with strong
 growth in revenue and profitability such as Globus Medical; products near
 commercialization such as Sientra, Pelikan, Oxford and Zogenix; and those
 with breakthrough products and technologies such as Aerovance, Centaurus,
 CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation. We
 plan to follow a similar investment strategy for Clarus II. With the
 diversity and depth of our team we believe we can leverage our experience
 to identify and help grow leading companies in the life sciences field."
 
     The Limited Partner base for Clarus II was effectively the same as in
 Clarus I. A small, select group of new high-quality investors who knew the
 firm well also participated.
 
     The Clarus Ventures team is led by Nicholas Galakatos, Dennis Henner,
 Jeffrey Leiden, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt
 Wheeler, an established group of investment professionals with deep and
 complementary backgrounds within the life sciences industry. The team
 uniquely balances broad investing expertise with leadership experience in
 major biotechnology and pharmaceutical companies.
 
     About Clarus Ventures
 
     Founded by a group of accomplished investment professionals with
 extensive and complementary industry backgrounds, Clarus Ventures is a life
 sciences venture capital firm with a team that has a long history of
 success in creating value. Internal operating experience combined with
 longstanding relationships with key opinion leaders and industry thought
 leaders and decision makers allow this team to identify unique investment
 opportunities and shepherd them to maturity. Clarus Ventures augments its
 core expertise of investing in biopharmaceuticals and medical technology
 with deep and diverse expertise in research and development,
 commercialization, business development and operations management at the
 global level. The firm has $1.2 billion under management and has offices in
 Cambridge, Mass., and South San Francisco, CA.
 
     For additional information on Clarus Ventures, please visit
 www.clarusventures.com.
 
 
CONTACTS: Nicholas Galakatos, Ph.D., Clarus Ventures, Tel.: 617-949-2223 Robert Liptak, Clarus Ventures, Tel.: 617-694-2222 Tony Russo, Russo Partners, Tel.: 212-845-4251

SOURCE Clarus Ventures, LLC

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.